School of Dentistry, Catholic University of Pelotas (UCPEL), Pelotas, RS, Brazil.
Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas (UFPEL), Pelotas, RS, Brazil.
J Dent. 2024 Oct;149:105311. doi: 10.1016/j.jdent.2024.105311. Epub 2024 Aug 17.
Intracanal medicaments, primarily calcium hydroxide, play a significant role in optimizing root canal disinfection. Recently, calcium silicate-based intracanal medicaments have emerged as potential alternatives. This scoping review sought to map the available evidence concerning the clinical and laboratory properties of these bioceramic medicaments.
The study protocol was registered a priori (https://osf.io/rnyuv/) and a systematic search strategy using relevant MeSH terms was employed.
The search was conducted across databases including the Cochrane Library, EMBASE, PubMed/MEDLINE, SciVerse Scopus, and Web of Science.
Studies that investigated the clinical and laboratory properties of calcium silicate-based intracanal medicaments were included.
Out of 1008 potentially relevant articles, 15 met the inclusion criteria. The majority of the studies came from Brazil, primarily focusing on Bio-C Temp (Angelus). The studies revealed acceptable biocompatibility, alkaline pH, and high calcium ion release. However, they showed reduced antibacterial activity compared to conventional calcium hydroxide formulations. Tooth discoloration beyond clinically acceptable thresholds was also a significant concern. A single clinical case report exhibited potential for periapical healing and root development, though this evidence is very limited. While current evidence is preliminary, high-quality clinical trials are essential to determine their clinical efficacy and safety in endodontic treatments.
Calcium silicate-based intracanal medicaments have lower antibacterial activity and potential for tooth discoloration compared to conventional calcium hydroxide-based medicaments. Given the available evidence, they cannot be recommended for routine clinical practice.
根管内药物，主要是氢氧化钙，在优化根管消毒方面发挥着重要作用。最近，基于硅酸钙的根管内药物已成为潜在的替代品。本范围综述旨在绘制有关这些生物陶瓷药物的临床和实验室特性的现有证据。
该研究方案事先在（https://osf.io/rnyuv/）进行了注册，并使用相关 MeSH 术语进行了系统的搜索策略。
该搜索在包括 Cochrane 图书馆、EMBASE、PubMed/MEDLINE、SciVerse Scopus 和 Web of Science 在内的数据库中进行。
纳入了研究硅酸钙基根管内药物临床和实验室特性的研究。
在 1008 篇潜在相关文章中，有 15 篇符合纳入标准。大多数研究来自巴西，主要集中在 Bio-C Temp（Angelus）上。这些研究显示出可接受的生物相容性、碱性 pH 值和高钙离子释放。然而，与传统的氢氧化钙制剂相比，它们显示出抗菌活性降低。超出临床可接受阈值的牙齿变色也是一个重大问题。仅有一项临床病例报告显示出根尖愈合和牙根发育的潜力，但这方面的证据非常有限。尽管目前的证据是初步的，但进行高质量的临床试验对于确定它们在牙髓治疗中的临床疗效和安全性至关重要。
与传统的氢氧化钙基药物相比，基于硅酸钙的根管内药物的抗菌活性较低，且有牙齿变色的潜力。鉴于现有证据，它们不能推荐用于常规临床实践。
